Alimera Sciences Announces Launch of ILUVIEN® for Uveitis in Spain
07 févr. 2022 08h00 HE
|
Alimera Sciences, Inc.
ATLANTA, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners...
Alimera Sciences to Present at the MicroCap Rodeo Winter Wonderland Best Ideas Virtual Investor Conference
04 févr. 2022 08h00 HE
|
Alimera Sciences, Inc.
ATLANTA, Feb. 04, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners...
Alimera Sciences to Participate in Upcoming January 2022 Investor Conferences
05 janv. 2022 08h00 HE
|
Alimera Sciences, Inc.
ATLANTA, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to...
Alimera Sciences Welcomes Ophthalmic Strategic Consultant Erin Parsons to Its Board of Directors
01 déc. 2021 07h30 HE
|
Alimera Sciences, Inc.
ATLANTA, Dec. 01, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners...
Alimera Sciences to Participate in Upcoming November 2021 Investor Conferences
09 nov. 2021 13h16 HE
|
Alimera Sciences, Inc.
ATLANTA, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners...
Alimera Sciences Announces Third Quarter 2021 Financial Results
28 oct. 2021 07h30 HE
|
Alimera Sciences, Inc.
Consolidated Net Revenue of $12.2 Million Down 2% vs. Third Quarter of 2020 and Up 14% vs. Second Quarter of 2021U.S. End User Demand up 15% vs. Third Quarter of 2020 and Second Quarter of 2021 ...
Alimera Sciences to Report Third Quarter 2021 Financial Results on Thursday, October 28, 2021, and Provide Corporate Update
21 oct. 2021 08h00 HE
|
Alimera Sciences, Inc.
ATLANTA, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera) a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners...
Recent 24-Month Real-World PALADIN Data Demonstrate the Ability of ILUVIEN® to Significantly Reduce Treatment Burden in Patients with Diabetic Macular Edema
13 oct. 2021 08h00 HE
|
Alimera Sciences, Inc.
PALADIN Study Data Presented at the American Society of Retina Specialists Shows That Post-ILUVIEN, the Percentage of Eyes Receiving One Yearly Treatment or Less Increased 3.2-Fold Compared to...
Alimera Sciences, Inc. to Present at the H.C. Wainwright 23rd Annual Global Investment Virtual Conference
02 sept. 2021 16h30 HE
|
Alimera Sciences, Inc.
ATLANTA, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to...
Alimera Sciences Announces Second Quarter 2021 Financial Results
13 août 2021 08h00 HE
|
Alimera Sciences, Inc.
Consolidated Net Revenue of $21.7 Million up 117% vs. Second Quarter of 2020Consolidated Net Product Revenue of $10.7 Million up 7% vs. Second Quarter of 2020Net Income of $7.6 Million vs. Net Loss of...